This editorial was written on 17 March and appears in the forthcoming 25 March issue of New Zealand Doctor. I knew it would be dated by the time publication day came around, but never anticipated such fast-moving change - Editor
Truth be told, it had been a long day by the time I started reading the comments on New Zealand Doctor’s website.
I found myself puzzling over the
Your patient with type 2 diabetes is not reaching HbA1c target after lifestyle changes and treatment with metformin. So what next? Dr Rick Cutfield takes an expert look at the second-line treatment options available in New Zealand, including newly funded DPP-4 inhibitor vildagliptin.